Breaking Down Ultragenyx Pharmaceutical: 10 Analysts Share Their Views
Portfolio Pulse from Benzinga Insights
Ultragenyx Pharmaceutical (NASDAQ:RARE) received mixed analyst ratings, with a majority being somewhat bullish. Analysts set a 12-month average price target of $89.7, slightly up from the previous $88.30. The company's financials show strong revenue growth but challenges in profitability and returns.
September 20, 2024 | 6:00 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Ultragenyx Pharmaceutical received mixed analyst ratings, with a majority being somewhat bullish. The average 12-month price target increased to $89.7. The company shows strong revenue growth but faces challenges in profitability and returns.
The mixed analyst ratings indicate a neutral short-term impact on Ultragenyx's stock price. The slight increase in the average price target suggests some positive sentiment, but the company's financial challenges in profitability and returns may offset this. The overall impact is neutral as the market digests these mixed signals.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100